Category: BioTech

Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

American Electric Power Posts Flat First-Quarter Earnings

American Electric Power AEP reported $0.80 ongoing EPS for the first quarter of 2013, flat from the year-ago quarter. Management reaffirmed ongoing 2013 EPS guidance of $3.05 to $3.25. The company recently announced a $0.49 quarterly dividend, a 4.3% increase and in line with the previously announced increased targeted dividend payout ratio of 60% to 70%. We are reaffirming our 2013 EPS forecast, our $48 … Continue reading American Electric Power Posts Flat First-Quarter Earnings

John MeadyLeave a comment
BioTech, Finance

Biotech Stock Focus: Celgene Beats Q2 Estimates With Strong Showings

In an impressive piece of news on the Stock Market, Celgene (CELG) reported second-quarter 2014 earnings (including stock-based compensation expenses) of 80 cents per share, which surpassed the Market Consensus Estimate by 3 cents. The company’s earnings were 70 cents per share in the year-ago quarter. Figures have been adjusted to reflect the two-for-one stock split effective last month. Investors were not pleased with the … Continue reading Biotech Stock Focus: Celgene Beats Q2 Estimates With Strong Showings

Richard Atkins
BioTech, Finance

Biotech Stock in Focus: Abbvie Q2 Earnings Impress Due to Humira Sales

AbbVie Inc (ABBV) reported second quarter 2014 earnings of 82 cents per share, unchanged from the year-ago earnings but surpassing the Consensus Estimate of 76 cents. Revenues increased 5% to $4.926 billion in the second quarter of 2014, surpassing the Consensus Estimate of $4.671 billion. Results were boosted by Humira’s strong performance. Including one-time items, second quarter 2014 earnings came in at 68 cents per … Continue reading Biotech Stock in Focus: Abbvie Q2 Earnings Impress Due to Humira Sales

Richard Atkins
BioTech, Finance

Biotech Stock in News: Puma Biotech Surges on Positive Results on Neratinib

Shares of Puma Biotechnology, Inc (PBYI) soared significantly after the company reported positive top-line results from the phase III trial on pipeline candidate, neratinib (PB272). Puma Biotech is evaluating neratinib for the extended adjuvant treatment of breast cancer. The phase III trial, ExteNET,(n=2821) is a double blind trial, which is evaluating neratinib versus placebo after adjuvant treatment with Roche’s (RHHBY) Herceptin in women suffering from … Continue reading Biotech Stock in News: Puma Biotech Surges on Positive Results on Neratinib

Richard Atkins
BioTech, Finance

Biotech Stock Top News: Gilead’s Q2 Earnings

There is no holding back Gilead Sciences’ (GILD – Analyst Report) hepatitis C virus (HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Consensus Estimate in Q2 on both revenues and earnings. The biopharmaceutical company’s second quarter adjusted earnings (including stock based compensation expenses) was of $2.32 per share. The second quarter 2014 … Continue reading Biotech Stock Top News: Gilead’s Q2 Earnings

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Range’s First-Quarter Results Come in Ahead of Expectations

Range Resources RRC reported first-quarter results Thursday. Quarterly production came in at 876 MMcfe per day, up 4% sequentially and 34% year over year and above both the company’s guidance and our forecast of 839 MMcfe/d. Growth was led by Range’s Marcellus acreage, where the firm continued to deliver impressive results across both its liquids-rich and dry-gas areas. Range maintained its 2013 guidance of 20%-25% … Continue reading Range’s First-Quarter Results Come in Ahead of Expectations

John MeadyLeave a comment